Back to Search
Start Over
Efficacy of Adalimumab with dose-reduced glucocorticoid for the treatment of Vogt-Koyanagi-Harada disease
- Source :
- Guoji Yanke Zazhi, Vol 22, Iss 12, Pp 2068-2072 (2022)
- Publication Year :
- 2022
- Publisher :
- Press of International Journal of Ophthalmology (IJO PRESS), 2022.
-
Abstract
- AIM: To evaluate the clinical efficacy of adalimumab(ADA)with dose-reduced glucocorticoid for the treatment of Vogt-Koyanagi-Harada disease(VKH).METHODS: A total of 21 patients(37 eyes)with VKH who received ADA therapy in the Department of Ophthalmology of our hospital from August 2020 to December 2021 were included. The interval of ADA administration was progressively extended after intraocular inflammation controlled and lasted for 3mo, and it returned to the initial treatment interval once the inflammation recurred. After follow-up for 12mo, anterior chamber cell(ACC)grade, vitreous haze(VH)grade, retinal/choroidal lesions, serous retinal detachment(SRD), best corrected visual acuity(BCVA), central macular thickness(CMT)and doses of glucocorticoid and immunosuppressant were compared before and after the first ADA injection. Treatment failure events and adverse reactions were recorded.RESULTS: Compared with baseline, the proportion of eyes with ACC grade ≤1+ and VH grade ≤1+ increased(P
Details
- Language :
- English
- ISSN :
- 16725123
- Volume :
- 22
- Issue :
- 12
- Database :
- Directory of Open Access Journals
- Journal :
- Guoji Yanke Zazhi
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7afb15ae39904def822657cf3f74044a
- Document Type :
- article
- Full Text :
- https://doi.org/10.3980/j.issn.1672-5123.2022.12.26